{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T12:37:46Z","timestamp":1786538266452,"version":"build-2736575974"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"The present work was supported by the Research Fund of Istanbul University.","award":["TDK-2019-34283"],"award-info":[{"award-number":["TDK-2019-34283"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Microbiol"],"DOI":"10.1186\/s12866-025-03914-8","type":"journal-article","created":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T03:25:14Z","timestamp":1742959514000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Investigation of the in vitro antimicrobial activity of eravacycline alone and in combination with various antibiotics against MDR Acinetobacter baumanni strains"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1648-6896","authenticated-orcid":false,"given":"Merve","family":"Ataman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8909-8398","authenticated-orcid":false,"given":"Berna \u00d6zbek","family":"\u00c7elik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,26]]},"reference":[{"issue":"3","key":"3914_CR1","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1097\/BCR.0b013e318234966c","volume":"33","author":"E Alp","year":"2012","unstructured":"Alp E, Coruh A, Gunay GK, Yontar Y, Doganay M. Risk factors for nosocomial infection and mortality in burn patients: 10 years of experience at a university hospital. J Burn Care Res. 2012;33(3):379\u201385.","journal-title":"J Burn Care Res"},{"issue":"9","key":"3914_CR2","doi-asserted-by":"publisher","first-page":"483","DOI":"10.2478\/pjs-2013-0075","volume":"85","author":"K Sieniawski","year":"2013","unstructured":"Sieniawski K, Kaczka K, Ruci\u0144ska M, Gagis L, Pomorski L. Acinetobacter baumannii nosocomial infections. Pol Przegl Chir. 2013;85(9):483\u201390.","journal-title":"Pol Przegl Chir"},{"issue":"5","key":"3914_CR3","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.3390\/microorganisms10051052","volume":"10","author":"B Havenga","year":"2022","unstructured":"Havenga B, Reyneke B, Waso-Reyneke M, Ndlovu T, Khan S, Khan W. Biological control of Acinetobacter baumannii: in vitro and in vivo activity, limitations, and combination therapies. Microorganisms. 2022;10(5):1052.","journal-title":"Microorganisms"},{"issue":"15","key":"3914_CR4","doi-asserted-by":"publisher","first-page":"5498","DOI":"10.3390\/ijms21155498","volume":"21","author":"S Monem","year":"2020","unstructured":"Monem S, Furmanek-Blaszk B, \u0141upkowska A, Kuczy\u0144ska-Wi\u015bnik D, Stojowska-Sw\u0119drzy\u0144ska K, Laskowska E. Mechanisms protecting Acinetobacter baumannii against multiple stresses triggered by the host immune response, antibiotics and Outside-Host environment. Int J Mol Sci. 2020;21(15):5498.","journal-title":"Int J Mol Sci"},{"key":"3914_CR5","doi-asserted-by":"publisher","first-page":"1070424","DOI":"10.3389\/fimmu.2022.1070424","volume":"13","author":"S Jeffreys","year":"2022","unstructured":"Jeffreys S, Chambers JP, Yu JJ, Hung CY, Forsthuber T, Arulanandam BP. Insights into Acinetobacter baumannii protective immunity. Front Immunol. 2022;13:1070424.","journal-title":"Front Immunol"},{"key":"3914_CR6","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3389\/fcimb.2017.00055","volume":"7","author":"CR Lee","year":"2017","unstructured":"Lee CR, Lee JH, Park M, et al. Biology of Acinetobacter baumannii: pathogenesis, antibiotic resistance mechanisms, and prospective treatment options. Front Cell Infect Microbiol. 2017;7:55.","journal-title":"Front Cell Infect Microbiol"},{"issue":"2","key":"3914_CR7","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3390\/antibiotics12020195","volume":"12","author":"P Li","year":"2023","unstructured":"Li P, Zhang S, Wang J, et al. Uncovering the secretion systems of Acinetobacter baumannii: structures and functions in pathogenicity and antibiotic resistance. Antibiot (Basel). 2023;12(2):195.","journal-title":"Antibiot (Basel)"},{"issue":"9","key":"3914_CR8","doi-asserted-by":"publisher","first-page":"3298","DOI":"10.1128\/AAC.48.9.3298-3304.2004","volume":"48","author":"I Marchand","year":"2004","unstructured":"Marchand I, Damier-Piolle L, Courvalin P, Lambert T. Expression of the RND-type efflux pump AdeABC in Acinetobacter baumannii is regulated by the aders two-component system. Antimicrob Agents Chemother. 2004;48(9):3298\u2013304.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5\u20136","key":"3914_CR9","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.cimid.2014.10.002","volume":"37","author":"C Chen","year":"2014","unstructured":"Chen C, Ke S, Li C, Chang C. The comparison of genotyping, antibiogram, and antimicrobial resistance genes between carbapenem-susceptible and -resistant Acinetobacter baumannii. Comp Immunol Microbiol Infect Dis. 2014;37(5\u20136):339\u201346.","journal-title":"Comp Immunol Microbiol Infect Dis"},{"issue":"1","key":"3914_CR10","doi-asserted-by":"publisher","first-page":"e00310","DOI":"10.1128\/mSphere.00310-16","volume":"2","author":"A Giammanco","year":"2017","unstructured":"Giammanco A, Cal\u00e0 C, Fasciana T, Dowzicky MJ. Global assessment of the activity of Tigecycline against multidrug-resistant gram-negative pathogens between 2004 and 2014 as part of the Tigecycline evaluation and surveillance trial. mSphere. 2017;2(1):e00310\u201316.","journal-title":"mSphere"},{"key":"3914_CR11","first-page":"05","volume":"30","author":"Centers for Disease Control and Prevention","year":"2019","unstructured":"Centers for Disease Control and Prevention. Acinetobacter in healthcare settings. Centers Disease Control Prev Consult\u00e9 Le. 2019;30:05\u201322.","journal-title":"Centers Disease Control Prev Consult\u00e9 Le"},{"issue":"4","key":"3914_CR12","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.jhin.2009.03.032","volume":"73","author":"KJ Towner","year":"2009","unstructured":"Towner KJ. Acinetobacter: an old friend, but a new enemy. J Hosp Infect. 2009;73(4):355\u201363.","journal-title":"J Hosp Infect"},{"issue":"3","key":"3914_CR13","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3390\/antibiotics9030119","volume":"9","author":"C Ayoub Moubareck","year":"2020","unstructured":"Ayoub Moubareck C, Hammoudi Halat D. Insights into Acinetobacter baumannii: A review of Microbiological, virulence, and resistance traits in a threatening nosocomial pathogen. Antibiot (Basel). 2020;9(3):119.","journal-title":"Antibiot (Basel)"},{"issue":"3","key":"3914_CR14","doi-asserted-by":"publisher","first-page":"373","DOI":"10.3390\/pathogens10030373","volume":"10","author":"I Kyriakidis","year":"2021","unstructured":"Kyriakidis I, Vasileiou E, Pana ZD, Tragiannidis A. Acinetobacter baumannii antibiotic resistance mechanisms. Pathogens. 2021;10(3):373.","journal-title":"Pathogens"},{"issue":"10","key":"3914_CR15","doi-asserted-by":"publisher","first-page":"6987","DOI":"10.1007\/s11033-021-06690-6","volume":"48","author":"S Ibrahim","year":"2021","unstructured":"Ibrahim S, Al-Saryi N, Al-Kadmy IMS, Aziz SN. Multidrug-resistant Acinetobacter baumannii as an emerging concern in hospitals. Mol Biol Rep. 2021;48(10):6987\u201398.","journal-title":"Mol Biol Rep"},{"issue":"5","key":"3914_CR16","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s40265-016-0545-8","volume":"76","author":"GG Zhanel","year":"2016","unstructured":"Zhanel GG, Cheung D, Adam H, et al. Review of Eravacycline, a novel fluorocycline antibacterial agent. Drugs. 2016;76(5):567\u201388.","journal-title":"Drugs"},{"issue":"3","key":"3914_CR17","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1128\/AAC.04809-14","volume":"59","author":"M Abdallah","year":"2015","unstructured":"Abdallah M, Olafisoye O, Cortes C, Urban C, Landman D, Quale J. Activity of Eravacycline against Enterobacteriaceae and Acinetobacter baumannii, including multidrug-resistant isolates, from new York City. Antimicrob Agents Chemother. 2015;59(3):1802\u20135.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"3914_CR18","doi-asserted-by":"publisher","first-page":"3840","DOI":"10.1128\/AAC.00436-16","volume":"60","author":"DM Livermore","year":"2016","unstructured":"Livermore DM, Mushtaq S, Warner M, Woodford N. In vitro activity of Eravacycline against Carbapenem-Resistant Enterobacteriaceae and Acinetobacter baumannii. Antimicrob Agents Chemother. 2016;60(6):3840\u20134.","journal-title":"Antimicrob Agents Chemother"},{"key":"3914_CR19","unstructured":"CLSI, Clinical & Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing. M100. 2022. https:\/\/clsi.org\/standards\/products\/microbiology\/documents\/m100\/. Accessed 1 Mar 2023."},{"key":"3914_CR20","unstructured":"CLSI, Clinical & Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically. M07. 2018. https:\/\/clsi.org\/standards\/products\/microbiology\/documents\/m07\/. Accessed 1 May 2023."},{"key":"3914_CR21","doi-asserted-by":"crossref","unstructured":"Drlica K. The mutant selection window and antimicrobial resistance. J Antimicrob Chemother. 2003;52(1):11\u20137.","DOI":"10.1093\/jac\/dkg269"},{"issue":"2","key":"3914_CR22","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/S0167-7012(00)00122-6","volume":"40","author":"S Stepanovic","year":"2000","unstructured":"Stepanovic S, Vukovic D, Dakic I, Savic B, Svabic-Vlahovic M. A modified microtiter-plate test for quantification of Staphylococcal biofilm formation. J Microbiol Methods. 2000;40(2):175\u20139.","journal-title":"J Microbiol Methods"},{"key":"3914_CR23","doi-asserted-by":"publisher","first-page":"2475067","DOI":"10.1155\/2016\/2475067","volume":"2016","author":"S Santajit","year":"2016","unstructured":"Santajit S, Indrawattana N. Mechanisms of antimicrobial resistance in ESKAPE pathogens. BioMed Res Int. 2016;2016:2475067.","journal-title":"BioMed Res Int"},{"issue":"9","key":"3914_CR24","doi-asserted-by":"publisher","first-page":"4176","DOI":"10.1128\/IAI.00318-08","volume":"76","author":"J Overhage","year":"2008","unstructured":"Overhage J, Campisano A, Bains M, Torfs EC, Rehm BH, Hancock RE. Human host defense peptide LL-37 prevents bacterial biofilm formation. Infect Immun. 2008;76(9):4176\u201382.","journal-title":"Infect Immun"},{"key":"3914_CR25","unstructured":"CLSI. Clinical & Laboratory Standards Institute. Methods for determining bactericidal activity of antimicrobial agents. Approved Guideline M26-A CLSI, 1999."},{"issue":"3","key":"3914_CR26","first-page":"365","volume":"7","author":"K Demirkan","year":"2007","unstructured":"Demirkan K. Terap\u00f6tik Ila\u00e7 Monitorizasyonu. J Crit Intensive Care. 2007;7(3):365\u20139.","journal-title":"J Crit Intensive Care"},{"key":"3914_CR27","first-page":"69","volume":"21","author":"E G\u00fcnal","year":"2014","unstructured":"G\u00fcnal E, Erdem H, Kinolonlar. \u0130\u00e7 Hastal\u0131klar\u0131 Dergisi. 2014;21:69\u201385.","journal-title":"\u0130\u00e7 Hastal\u0131klar\u0131 Dergisi"},{"issue":"7","key":"3914_CR28","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1007\/s40262-022-01137-y","volume":"61","author":"GM Pais","year":"2022","unstructured":"Pais GM, Chang J, Barreto EF, et al. Clinical pharmacokinetics and pharmacodynamics of cefepime. Clin Pharmacokinet. 2022;61(7):929\u201353.","journal-title":"Clin Pharmacokinet"},{"key":"3914_CR29","doi-asserted-by":"publisher","first-page":"1368397","DOI":"10.1155\/2019\/1368397","volume":"2019","author":"RA Sep\u00falveda","year":"2019","unstructured":"Sep\u00falveda RA, Downey P, Soto D, et al. Plasma and renal cortex meropenem concentrations in patients undergoing percutaneous renal biopsy. Biomed Res Int. 2019;2019:1368397.","journal-title":"Biomed Res Int"},{"issue":"1","key":"3914_CR30","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1097\/QCO.0000000000000518","volume":"32","author":"J Garnacho-Montero","year":"2019","unstructured":"Garnacho-Montero J, Timsit JF. Managing Acinetobacter baumannii infections. Curr Opin Infect Dis. 2019;32(1):69\u201376.","journal-title":"Curr Opin Infect Dis"},{"issue":"3","key":"3914_CR31","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s40265-019-01067-3","volume":"79","author":"LJ Scott","year":"2019","unstructured":"Scott LJ, Eravacycline. A review in complicated intra-abdominal infections. Drugs. 2019;79(3):315\u201324.","journal-title":"Drugs"},{"issue":"2","key":"3914_CR32","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1128\/CMR.9.2.148","volume":"9","author":"E Bergogne-B\u00e9r\u00e9zin","year":"1996","unstructured":"Bergogne-B\u00e9r\u00e9zin E, Towner KJ. Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin Microbiol Rev. 1996;9(2):148\u201365.","journal-title":"Clin Microbiol Rev"},{"issue":"3","key":"3914_CR33","doi-asserted-by":"publisher","first-page":"291","DOI":"10.4103\/0974-777X.68538","volume":"2","author":"V Manchanda","year":"2010","unstructured":"Manchanda V, Sanchaita S, Singh N. Multidrug resistant acinetobacter. J Glob Infect Dis. 2010;2(3):291\u2013304.","journal-title":"J Glob Infect Dis"},{"key":"3914_CR34","doi-asserted-by":"crossref","unstructured":"Liu H, Hu D, Wang D, Wu H, Pan Y, Chen X et al. In vitro analysis of synergistic combination of polymyxin B with 12 other antibiotics against MDR Acinetobacter baumannii isolated from a Chinese tertiary hospital. J Antibiot (Tokyo). 2022;20\u20136.","DOI":"10.1038\/s41429-022-00573-z"},{"issue":"Suppl 1","key":"3914_CR35","doi-asserted-by":"publisher","first-page":"S34","DOI":"10.1093\/ofid\/ofy293","volume":"6","author":"AC Gales","year":"2019","unstructured":"Gales AC, Seifert H, Gur D, Castanheira M, Jones RN, Sader HS. Antimicrobial susceptibility of Acinetobacter calcoaceticus-Acinetobacter baumannii complex and Stenotrophomonas maltophilia clinical isolates: results from the SENTRY antimicrobial surveillance program (1997\u20132016). Open Forum Infect Dis. 2019;6(Suppl 1):S34\u201346.","journal-title":"Open Forum Infect Dis"},{"issue":"3","key":"3914_CR36","doi-asserted-by":"publisher","first-page":"340","DOI":"10.5505\/vtd.2020.73384","volume":"27","author":"T Ozekinci","year":"2020","unstructured":"Ozekinci T, Habip Z, Onder N, Ko\u00e7oglu ME. Antibiotic resistance of Acinetobacter baumannii strains isolated in 2015\u20132018 years. Van Med J. 2020;27(3):340\u20134.","journal-title":"Van Med J"},{"issue":"5","key":"3914_CR37","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1093\/jac\/dkm305","volume":"60","author":"KS Ko","year":"2007","unstructured":"Ko KS, Suh JY, Kwon KT, et al. High rates of resistance to colistin and polymyxin B in subgroups of Acinetobacter baumannii isolates from Korea. J Antimicrob Chemother. 2007;60(5):1163\u20137.","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"3914_CR38","first-page":"107","volume":"67","author":"E \u00c7a\u011flan","year":"2020","unstructured":"\u00c7a\u011flan E, Nigiz \u015e, Sancak B, G\u00fcr D. Resistance and heteroresistance to colistin among clinical isolates of Acinetobacter baumannii. Acta Microbiol Immunol Hung. 2020;67(2):107\u201311.","journal-title":"Acta Microbiol Immunol Hung"},{"issue":"7","key":"3914_CR39","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.3855\/jidc.16724","volume":"16","author":"\u0130M Mumcuoglu","year":"2022","unstructured":"Mumcuoglu \u0130M, Caglar H, Erdem D, Aypak A, Gun P, Kursun S, et al. Evaluation of the secondary bacterial infections of respiratory tract in Covid 19 patients. J Infect Dev Ctries. 2022;16(7):1131\u20137.","journal-title":"J Infect Dev Ctries"},{"issue":"8","key":"3914_CR40","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/s41429-019-0188-6","volume":"72","author":"HS Ozger","year":"2019","unstructured":"Ozger HS, Cuhadar T, Yildiz SS, et al. In vitro activity of Eravacycline in combination with colistin against carbapenem-resistant A. baumannii isolates. J Antibiot (Tokyo). 2019;72(8):600\u20134.","journal-title":"J Antibiot (Tokyo)"},{"key":"3914_CR41","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.jgar.2022.05.020","volume":"30","author":"Y Li","year":"2022","unstructured":"Li Y, Cui L, Xue F, Wang Q, Zheng B. Synergism of Eravacycline combined with other antimicrobial agents against carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii. J Glob Antimicrob Resist. 2022;30:56\u20139.","journal-title":"J Glob Antimicrob Resist"},{"issue":"5\u20136","key":"3914_CR42","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/j.1365-3164.2009.00856.x","volume":"20","author":"JM Blondeau","year":"2009","unstructured":"Blondeau JM. New concepts in antimicrobial susceptibility testing: the mutant prevention concentration and mutant selection window approach. Vet Dermatol. 2009;20(5\u20136):383\u201396.","journal-title":"Vet Dermatol"},{"issue":"9","key":"3914_CR43","doi-asserted-by":"publisher","first-page":"3998","DOI":"10.1128\/AAC.00264-10","volume":"54","author":"Y Cai","year":"2010","unstructured":"Cai Y, Li R, Liang B, Bai N, Liu Y, Wang R. In vitro antimicrobial activity and mutant prevention concentration of colistin against Acinetobacter baumannii. Antimicrob Agents Chemother. 2010;54(9):3998\u20139.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"3914_CR44","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1093\/jac\/dkg376","volume":"52","author":"X Zhao","year":"2003","unstructured":"Zhao X. Clarification of MPC and the mutant selection window concept. J Antimicrob Chemother. 2003;52(4):731\u20133.","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"3914_CR45","doi-asserted-by":"publisher","first-page":"623","DOI":"10.3390\/antibiotics13070623","volume":"13","author":"A Mishra","year":"2024","unstructured":"Mishra A, Aggarwal A, Khan F. Medical device-associated \u0131nfections caused by biofilm-forming microbial pathogens and controlling strategies. Antibiot (Basel). 2024;13(7):623.","journal-title":"Antibiot (Basel)"},{"key":"3914_CR46","unstructured":"Tamma PD, Cosgrove SE, Maragakis LL. Combination therapy for treatment of infections with gram-negative bacteria."},{"key":"3914_CR47","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.1093\/eurheartj\/ehv319","volume":"36","author":"G Habib","year":"2015","unstructured":"Habib G, Lancellotti P, Antunes MJ, Bongiorni MG, Casalta JP, Del Zotti F, et al. 2015 ESC guidelines for the management of infective endocarditis. Eur Heart J. 2015;36:3075\u2013123.","journal-title":"Eur Heart J"},{"key":"3914_CR48","doi-asserted-by":"crossref","unstructured":"Drusano GL, Neely M, Van Guilder M, Schumitzky A, Brown D, Fikes S et al. Analysis of combination drug therapy to develop regimens with shortened duration of treatment for tuberculosis. PLoS ONE. 2014;9(7).","DOI":"10.1371\/journal.pone.0101311"},{"issue":"1","key":"3914_CR49","first-page":"1","volume":"8","author":"X Xu","year":"2018","unstructured":"Xu X, Xu L, Yuan G, Wang Y, Qu Y, Zhou M. Synergistic combination of two antimicrobial agents closing each other\u2019s mutant selection windows to prevent antimicrobial resistance. Sci Rep. 2018;8(1):1\u20137.","journal-title":"Sci Rep"},{"issue":"10","key":"3914_CR50","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.3390\/antibiotics11101298","volume":"11","author":"MS Deolankar","year":"2022","unstructured":"Deolankar MS, Carr RA, Fliorent R, Roh S, Fraimow H, Carabetta VJ. Evaluating the efficacy of Eravacycline and Omadacycline against extensively Drug-Resistant Acinetobacter baumannii patient isolates. Antibiot (Basel). 2022;11(10):1298.","journal-title":"Antibiot (Basel)"},{"key":"3914_CR51","first-page":"276","volume":"32","author":"HS Ozger","year":"2021","unstructured":"Ozger HS, Cuhadar T, Yildiz SS, Gulmez ZD, Tunccan OG, Kalkanci A, et al. In vitro activity of Eravacycline in combination with colistin against OXA-type carbapenemase producing Klebsiella pneumoniae isolates. Gazi Med J. 2021;32:276\u201380.","journal-title":"Gazi Med J"}],"container-title":["BMC Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12866-025-03914-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12866-025-03914-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12866-025-03914-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T05:42:59Z","timestamp":1743313379000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmicrobiol.biomedcentral.com\/articles\/10.1186\/s12866-025-03914-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,26]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3914"],"URL":"https:\/\/doi.org\/10.1186\/s12866-025-03914-8","relation":{},"ISSN":["1471-2180"],"issn-type":[{"value":"1471-2180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,26]]},"assertion":[{"value":"12 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki, and the protocol was approved by the Istanbul University Istanbul Faculty of Medicine Clinical Research Ethics Committee Istanbul, Turkey, under the ethical code 2019\/454.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"All enrolled subjects provided written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"167"}}